This innovative metric identified a high‐risk OSA subset resistant to neoadjuvant chemotherapy with a poor prognosis, characterized by molecular traits such as MYC overexpression, upregulated mTORC1 signalling and decreased immune cell infiltration. Here, MYC is linked to obstructive sleep apnea syndrome.